Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06162351Phase 2Terminated

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Role: collaborator

NCT06337630Phase 1Terminated

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors

Role: collaborator

NCT06894745Phase 1Recruiting

PET [89Zr]DFO-starPEG in Solid Tumors

Role: collaborator

NCT02646852Phase 1Completed

A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded